An internal standard for the quantification of febuxostat
Related Products
Unlabeled Version(s)
14127Febuxostat
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Febuxostat-d9

Item No. 25033

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-[3-cyano-4-[2-(methyl-d3)propoxy-1,1,2,3,3,3-d6]phenyl]-4-methyl-5-thiazolecarboxylic acid
CAS Number
1246819-50-0
Molecular Formula
C16H7D9N2O3S
Formula Weight
325.4
Purity
≥99% deuterated forms (d1-d9)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 1 mg/ml
SMILES
CC1=C(C(O)=O)SC(C2=CC(C#N)=C(OC([2H])([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C=C2)=N1
InChi Code
InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)/i1D3,2D3,8D2,9D
InChi Key
BQSJTQLCZDPROO-KIROAFHOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $288

    Add
    Product Description

    Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat (Item No. 14127) by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase.1 It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively).2 It is 10-30 times more potent than the hypoxanthine analog allopurinol (Item No. 10012597; Kis = 0.7 nM and 0.7 μM, respectively).3,4 Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg).2 It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day.5 Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE).6 Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Okamoto, K., Eger, B.T., Nishino, T., et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. The Journal of Biological Chemisty 278(3), 1848-1855 (2003).

    2. Osada, Y., Tsuchimoto, M., Fukushima, H., et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur. J. Pharmacol. 241(2-3), 183-188 (1993).

    3. Takano, Y., Hase-Aoki, K., Horiuchi, H., et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 76(16), 1835-1847 (2005).

    4. Bisht, M., and Bist, S.S. Febuxostat: A novel agent for management of hyperuricemia in gout. Indian J. Pharm. Sci. 73(6), 597-600 (2011).

    5. Nakatsu, Y., Seno, Y., Kushiyama, A., et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am. J. Physiol. Gastrointest. Liver Physiol. 309(1), G42-G51 (2015).

    6. Honorat, J.A., Nakatsuji, Y., Shimizu, M., et al. Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. PLoS One 12(11), e0187215 (2017).